Approval heralds new generation of kinase inhibitors?
Fletcher
L
L
D000970:Antineoplastic Agents; D001549:Benzamides; D001709:Biotechnology / Q000639:trends*; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000737:chemistry; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D000068877:Imatinib Mesylate; D008958:Models, Molecular; D010770:Phosphotransferases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D010879:Piperazines; D011743:Pyrimidines; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D010770:Phosphotransferases; D017871:Calcium-Calmodulin-Dependent Protein Kinases